G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges
By September 2025, the FDA had issued more than 50 warning letters to GLP-1 compounders and manufacturers with confirmed DOJ involvement, and 40-plus state attorneys general formally petitioned the FDA about counterfeit peptides entering the US market
Side effects were dose-dependent, which is why the dose is titrated upward gradually rather than starting at the full dose
Standard insulin syringes can leave 0.05ml to 0.08ml behind per injection, which adds up quickly over a 48-week treatment course
The literature overall suggests the degree of muscle versus fat loss is not different with GLP-1s than with weight loss through other methods
Penta deca peptide arginate upregulates growth hormone receptors in fibroblasts, while growth hormone secretagogues like CJC-1295 and Ipamorelin increase growth hormone levels